이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Frequency-Dependent Effects of Percutaneous Femoral Nerve Stimulation on Quadriceps Strength (Motor_pPNS)

2026년 11월 10일 업데이트: Xavier Picañol Parraga, Hospital Clinic of Barcelona

Femoral Nerve Stimulation on Knee Extension Strength in Patellar Tendinopathy: A Randomized Crossover Trial

Peripheral nerve stimulation (PNS) is used to manage musculoskeletal pain and may also influence the neural mechanisms involved in voluntary muscle activation. However, whether different stimulation protocols produce distinct effects on muscle strength in individuals with persistent musculoskeletal pain remains unclear.

This randomized, blinded, crossover clinical trial investigates the acute effects of three femoral nerve stimulation protocols on quadriceps muscle function in individuals with persistent patellar tendinopathy. Each participant receives three interventions in a randomized sequence, separated by washout periods of at least 7 days: (1) high-frequency percutaneous peripheral nerve stimulation (HF-pPNS; 100 Hz), (2) low-frequency percutaneous peripheral nerve stimulation (LF-pPNS; 2 Hz), and (3) sensory-level transcutaneous electrical nerve stimulation (s-TENS; 100 Hz). Percutaneous interventions are administered under ultrasound guidance, whereas s-TENS is delivered using surface electrodes.

Quadriceps maximal voluntary contraction (MVC) and rate of force development (RFD) are assessed before stimulation and at 2, 10, 15, and 30 minutes after each intervention. Pain experienced during muscle strength testing, intervention tolerability, and adverse events are also evaluated.

The primary objective is to determine whether these stimulation protocols produce different acute changes in voluntary quadriceps force production. The study also examines interindividual variability in motor responses and explores their associations with pain during voluntary contraction and baseline clinical status.

연구 개요

상태

완전한

정황

개입 / 치료

연구 유형

중재적

등록 (실제)

19

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • Barcelona
      • Barcelona, Barcelona, 스페인, 08020
        • Blanquerna University

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

설명

Inclusion Criteria

  • Adults aged 18-40 years.
  • Individuals with clinically diagnosed patellar tendinopathy lasting ≥3 months.
  • Ultrasound findings consistent with patellar tendinopathy, including tendon thickening, hypoechoic areas, or neovascularization.
  • Pain during tendon-loading activities (e.g., jumping, running, or squatting).
  • Ability to perform maximal voluntary isometric quadriceps contractions and comply with all experimental procedures and sessions.
  • Ability and willingness to provide written informed consent prior to participation.

Exclusion Criteria

  • Knee surgery or traumatic knee injury within the preceding 12 months.
  • Partial or complete patellar tendon rupture.
  • Neurological or neuromuscular disorders affecting lower-limb motor function, including radiculopathy or peripheral neuropathy.
  • Contraindications to electrical stimulation or percutaneous procedures, including implanted electrical devices, skin infections, or open wounds at the stimulation site.
  • Use of analgesics or anti-inflammatory medications, or receipt of corticosteroid injections, within the preceding 48 hours.
  • Participation in another interventional study within the preceding 30 days.
  • Pregnancy or suspected pregnancy.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: High-frequency percutaneous peripheral nerve stimulation (HF-pPNS)

Participants receive HF-pPNS as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

High-frequency percutaneous peripheral nerve stimulation (HF-pPNS) is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Valencia, Spain), which generates symmetrical biphasic pulses. The femoral nerve is identified at the inguinal level using a SonoScape E1 Exp ultrasound system (SonoScape Medical Corp., Shenzhen, China). Under real-time ultrasound guidance, a sterile acupuncture needle (0.30 × 50 mm) is inserted in-plane and positioned lateral to the femoral nerve, avoiding adjacent vessels. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Stimulation is administered at 100 Hz in five 5-second trains separated by 55-second rest intervals. Intensity is adjusted to the highest pain-free current eliciting visible quadriceps contraction. Participants receive one session, with at least 7 days between crossover conditions.

다른 이름들:
  • HF-pPNS
실험적: Low-frequency percutaneous peripheral nerve stimulation (LF-pPNS)

Participants receive LF-pPNS as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

Low-frequency percutaneous peripheral nerve stimulation (LF-pPNS) is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Valencia, Spain), which generates symmetrical biphasic pulses. The femoral nerve is identified at the inguinal level using a SonoScape E1 Exp ultrasound system (SonoScape Medical Corp., Shenzhen, China). Under real-time ultrasound guidance, a sterile acupuncture needle (0.30 × 50 mm) is inserted in-plane and positioned lateral to the femoral nerve, avoiding adjacent vessels. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Stimulation is administered continuously at 2 Hz for 16 minutes. Intensity is adjusted to the highest pain-free current eliciting visible quadriceps contraction. Participants receive one session, with at least 7 days between crossover conditions.

다른 이름들:
  • LF-pPNS
활성 비교기: Sensory-level transcutaneous femoral nerve stimulation (s-TENS)

Participants receive s-TENS targeting the femoral nerve as one of three conditions in a randomized crossover trial. Each participant undergoes this condition once, with a minimum 7-day washout period between experimental sessions.

Sensory-level transcutaneous electrical nerve stimulation (s-TENS) is administered targeting the femoral nerve at the inguinal level. The femoral nerve is identified under ultrasound guidance (SonoScape E1 Exp, SonoScape Medical Corp., China), and a self-adhesive surface electrode (5 × 5 cm) is positioned over the nerve. A surface return electrode is placed over the vastus medialis, approximately 4 cm medial to the superior pole of the patella. Electrical stimulation is delivered using the EPTE BYPOLAR SYSTEM (ION CLINIC SL, Spain), generating symmetrical biphasic pulses continuously at 100 Hz for 16 minutes. Intensity is individually adjusted to elicit a clear paresthetic sensation without visible quadriceps contraction. Each participant receives one s-TENS session, with a minimum 7-day washout between crossover conditions.

다른 이름들:
  • s-TENS

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in Quadriceps Maximal Isometric Voluntary Contraction
기간: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.

Quadriceps maximal voluntary isometric contraction (MVC) is measured on the symptomatic limb using a Chronojump Force Sensor Kit (Chronojump, Barcelona, Spain). Participants are seated with the hip flexed at 90° and the knee positioned at 60°. Following a standardized warm-up and familiarization procedure, participants perform three 4-second maximal voluntary isometric knee-extension contractions, separated by 10-second rest intervals. Real-time visual force feedback is provided, and participants are instructed to contract as fast and as hard as possible from a relaxed state. MVC is defined as the highest peak force recorded across the three trials, expressed in Newtons (N). Absolute and relative changes from baseline are assessed following each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS).

Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.

2차 결과 측정

결과 측정
측정값 설명
기간
Change in Quadriceps Rate of Force Development
기간: Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.

Quadriceps rate of force development (RFD) is assessed on the symptomatic limb using a Chronojump Force Sensor Kit (Chronojump, Barcelona, Spain). Participants perform three 4-second maximal voluntary isometric knee-extension contractions, separated by 10-second rest intervals, while instructed to contract as fast and as hard as possible. RFD is calculated from the force-time curve as the slope of force increase during the first 250 milliseconds following contraction onset, expressed in Newtons per second (N/s). Absolute and relative changes from baseline are assessed following each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS).

Baseline (pre-intervention), and at 2 minutes, 10 minutes, 15 minutes, and 30 minutes post-intervention.
Incidence of Adverse Events Assessed Through Post-Intervention Questionnaires
기간: Immediately after each intervention session.

Adverse events potentially associated with peripheral nerve stimulation are assessed using a structured questionnaire completed at the end of each experimental session. Participants report the presence and intensity of sensory symptoms (pain, burning, itching), local skin reactions (erythema, swelling, bruising), and systemic symptoms (fatigue, headache, nausea). Additional unexpected symptoms can also be reported. Symptom intensity is assessed using a numerical rating scale (NRS; 0-10). Adverse events are recorded by type and severity, and their incidence is expressed as the number and percentage of participants reporting each event under each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS). Differences in adverse event frequency and intensity are evaluated across stimulation conditions.

Immediately after each intervention session.
Pain Intensity Evoked by Quadriceps Contraction
기간: Immediately after post-intervention quadriceps strength testing during each experimental session.

Pain intensity experienced during quadriceps maximal voluntary isometric contraction (MVC) is assessed using a 10-cm visual analog scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain). Participants report the intensity of pain experienced during the strength-testing procedure immediately after its completion. Pain scores are recorded for each stimulation condition (HF-pPNS, LF-pPNS, and s-TENS) to characterize pain experienced during voluntary force production and explore its association with changes in quadriceps strength.

Immediately after post-intervention quadriceps strength testing during each experimental session.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2025년 9월 20일

기본 완료 (실제)

2026년 1월 14일

연구 완료 (실제)

2026년 11월 4일

연구 등록 날짜

최초 제출

2025년 11월 15일

QC 기준을 충족하는 최초 제출

2025년 11월 15일

처음 게시됨 (실제)

2025년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 20250405

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data underlying the results reported in the published article will be available from the corresponding author upon reasonable request. These data may include maximal voluntary contraction (MVC), rate of force development (RFD), pain ratings, baseline clinical characteristics, stimulation conditions, and adverse events. Data sharing will be subject to applicable ethical approvals, institutional policies, and data protection requirements. Requests will be evaluated based on their scientific rationale and methodological soundness.

IPD 공유 기간

De-identified individual participant data will be available upon reasonable request beginning at the time of publication of the study results and for a period of five years thereafter.

IPD 공유 액세스 기준

De-identified individual participant data underlying the published results will be available to qualified researchers upon reasonable request to the corresponding author. Requests must include a scientifically sound research proposal describing the intended use of the data. Access will be subject to approval by the research team and compliance with applicable ethical, institutional, and data protection requirements. A data-sharing agreement may be required before data transfer.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .